Foresite Capital Management IV

Latest statistics and disclosures from Foresite Capital Management IV's latest quarterly 13F-HR filing:

Tip: Access up to 7 years of quarterly data

Positions held by Foresite Capital Management IV consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Foresite Capital Management IV

Companies in the Foresite Capital Management IV portfolio as of the June 2021 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Kinnate Biopharma (KNTE) 30.4 $225M 9.7M 23.28
Lyell Immunopharma 29.2 $216M NEW 13M 16.24
Pharvaris N V (PHVS) 8.2 $61M 3.3M 18.63
Aclaris Therapeutics (ACRS) 8.1 $60M 3.4M 17.56
Quantum-Si Incorporated Com Cl A 7.4 $55M NEW 4.5M 12.26
Kura Oncology (KURA) 5.2 $39M 1.8M 20.85
Nurix Therapeutics (NRIX) 4.3 $32M -2% 1.2M 26.53
Relay Therapeutics (RLAY) 2.8 $20M -73% 556k 36.59
Cytokinetics (CYTK) 1.5 $11M -38% 545k 19.79
Olema Pharmaceuticals (OLMA) 1.3 $9.6M -12% 342k 27.98
Cymabay Therapeutics (CBAY) 1.1 $7.8M 1.8M 4.36
Decibel Therapeutics (DBTX) 0.3 $2.6M 298k 8.60
Tempest Therapeutics 0.3 $2.1M NEW 190k 11.18

Past Filings by Foresite Capital Management IV

SEC 13F filings are viewable for Foresite Capital Management IV going back to 2017